

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7786822

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ANJI PHARMA (US) LLC	09/30/2022
RECEIVING PARTY DATA	
Name:	ANJI PHARMACEUTICALS INC.
Street Address:	245 MAIN STREET
City:	CAMBRIDGE
State/Country:	MASSACHUSETTS
Postal Code:	02142
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16273079
CORRESPONDENCE DATA	
Fax Number:	(617)832-7000
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 832-1754
Email:	patentdocketing@foleyhoag.com, alucas@foleyhoag.com
Correspondent Name:	FOLEY HOAG LLP
Address Line 1:	155 SEAPORT BOULEVARD
Address Line 4:	BOSTON, MASSACHUSETTS 02210-2600
ATTORNEY DOCKET NUMBER:	AJH-00705
NAME OF SUBMITTER:	ALYSON LUCAS
SIGNATURE:	/Alyson Lucas/
DATE SIGNED:	02/08/2023
Total Attachments: 11	
source=AJH-004_5_6_7_8 Assignment Anji Pharma (US) LLC to Anji Pharmaceuticals Inc. - Signed#page1.tif	
source=AJH-004_5_6_7_8 Assignment Anji Pharma (US) LLC to Anji Pharmaceuticals Inc. - Signed#page2.tif	
source=AJH-004_5_6_7_8 Assignment Anji Pharma (US) LLC to Anji Pharmaceuticals Inc. - Signed#page3.tif	
source=AJH-004_5_6_7_8 Assignment Anji Pharma (US) LLC to Anji Pharmaceuticals Inc. - Signed#page4.tif	
source=AJH-004_5_6_7_8 Assignment Anji Pharma (US) LLC to Anji Pharmaceuticals Inc. - Signed#page5.tif	
source=AJH-004_5_6_7_8 Assignment Anji Pharma (US) LLC to Anji Pharmaceuticals Inc. - Signed#page6.tif	

source=AJH-004_5_6_7_8 Assignment Anji Pharma (US) LLC to Anji Pharmaceuticals Inc. - Signed#page7.tif
source=AJH-004_5_6_7_8 Assignment Anji Pharma (US) LLC to Anji Pharmaceuticals Inc. - Signed#page8.tif
source=AJH-004_5_6_7_8 Assignment Anji Pharma (US) LLC to Anji Pharmaceuticals Inc. - Signed#page9.tif
source=AJH-004_5_6_7_8 Assignment Anji Pharma (US) LLC to Anji Pharmaceuticals Inc. - Signed#page10.tif
source=AJH-004_5_6_7_8 Assignment Anji Pharma (US) LLC to Anji Pharmaceuticals Inc. - Signed#page11.tif

ASSIGNMENT

ASSIGNMENT

THIS ASSIGNMENT is made as of this 30th day of September, 2022, by Anji Pharma (US) LLC, having its principal place of business at 245 Main Street, Cambridge, MA 02142 (the "Assignor"), to Anji Pharmaceuticals Inc., (hereinafter "ASSIGNEE"), a corporation organized and existing under the laws of Delaware, having its principal place of business at 245 Main Street, Cambridge, MA 02142 (the "Assignee").

WHEREAS, Assignor is the owner of the patent applications listed in the attached schedule (the "Patent Applications"),

WHEREAS, Assignor wishes to transfer and assign to Assignee, and Assignee desires to accept the transfer and assignment of, all of Assignor's right, title and interest in, to and under the Patent Applications,

NOW, THEREFORE, in consideration of the foregoing and of other good and valuable consideration, the receipt, adequacy and legal sufficiency of which are hereby acknowledged, Assignor hereby sells, assigns and transfers unto said Assignee, its successors, assigns and legal representatives, Assignor's entire right, title and interest in and throughout the United States of America, its territories and all foreign countries, in and to said invention(s) as described in the Patent Applications, together with the Assignor's entire right, title and interest in and to said Patent Applications and such Letters Patents as may issue thereon, and any substitution, reissue, continuation, divisional, revival and foreign counterparts thereof and including the right to claim priority under any applicable statute, treaty or convention based on said applications; said invention(s), applications and Letters Patents to be held and enjoyed by said Assignee for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said Letters Patents may be granted as fully and entirely as the same would have been held by us had this assignment not been made; Assignor hereby conveys all rights arising under or pursuant to any and all international agreements, treaties or laws relating to the protection of industrial property by filing any such applications or Letters Patents including the right to sue for and collect damages and other recoveries for past infringement thereof, all rights to initiate proceedings before government and administrative bodies, and all files, records and other materials arising from the prosecution, exploitation, or defense of rights and registrations pertaining to the applications or Letters Patents. Assignor hereby acknowledges that this assignment, being of our entire right, title and interest in and to said Patent Applications, carries with it the right in Assignee to apply for and obtain from competent authorities in all countries of the world any and all Letters Patents by attorneys and agents of Assignee's selection and the right to procure the grant of all such Letters Patents to Assignee for its own name as Assignee of the entire right, title and interest therein;


Assignor hereby authorizes and requests the Commissioner of Patents of the United States to issue such Letters Patents as shall be granted upon said application or applications based thereon to said Assignee, its successors, assigns, and legal representatives.

ASSIGNMENT

IN WITNESS WHEREOF, the parties hereto have caused this Assignment of Patents to be duly executed as of the date first written above.

ASSIGNOR:

Anji Pharma (US) LLC

By: 

Name: Brian Hubbard

Title: Manager

ASSIGNEE:

Anji Pharmaceuticals Inc.

By: _____

Name: Michael Serrano-Wu

Title: Chief Scientific Officer

ASSIGNMENT

IN WITNESS WHEREOF, the parties hereto have caused this Assignment of Patents to be duly executed as of the date first written above.

ASSIGNOR:

Anji Pharma (US) LLC

By: _____

Name: Brian Hubbard

Title: Manager

ASSIGNEE:

Anji Pharmaceuticals Inc.

By: _____

Name: Michael Serrano-Wu

Title: Chief Scientific Officer

SCHEDULE

SCHEDULE

Jurisdiction	Status	Appl. No.	Filing Date	Patent No.	Issue Date
US	Granted	13/978514	06-Jan-2012	9050292	09-Jun-2015
US	Granted	14/733750	08-Jun-2015	9463170	11-Oct-2016
US	Granted	15/289713	10-Oct-2016	9962344	08-May-2018
US	Granted	15/971942	04-May-2018	10610500	07-Apr-2020
WO	Nationalized	PCT/US12/20548	06-Jan-2012		
EA	Granted	201370154	07-Aug-2013	039943	30-Mar-2022
ZA	Granted	2013/04702	24-Jun-2013	2013/04702	25-Nov-2015
AU	Pending	2022201075	17-Feb-2022		
AU	Granted	2012204162	12-Jul-2013	2012204162	03-Aug-2017
AU	Granted	2017206190	19-Jul-2017	2017206190	14-Nov-2019
AU	Granted	2019253780	21-Oct-2019	2013253780	10-Mar-2022
CA	Granted	2823397	27-Jun-2013	2823397	10-Mar-2020
HK	Published	42021034860.3	12-Jul-2021		

SCHEDULE

HK	Granted	14104318.1	07-May-2014	HK1190950	23-Apr-2021
MX	Granted	MX/a/2013/007884	05-Jul-2013	372415	18-Mar-2020
BR	Granted	1120130174110	05-Jul-2013	BR112013017411-0	22-Mar-2022
US	Expired	61/430914	07-Jan-2011		
IL	Granted	227130	06-Jan-2012	227130	01-Jul-2020
EP	Granted, Validated in MT, CY, AL, LI, SM, LT, BG, RO, RS, LV, HR, EE, MK, IS, SK, SI, CZ, TR, PL, HU, NO, FI, AT, BE, DK, FR, DE, GR, IT, IE, LU, MC, NL, PT, ES, SE, CH, and GB	12732408.5	22-Jul-2013	2661266	16-Sep-2020
EP	Published	20191580.8	18-Aug-2020		
SG	Abandoned	201305188-3	06-Jan-2012		
SG	Pending	10201607085W	25-Aug-2016		

SCHEDULE

US	Granted	13/547022	11-Jul-2012	8796338	05-Aug-2014
US	Granted	14/370449	08-Oct-2014	9480663	01-Nov-2016
US	Granted	14/451323	04-Aug-2014	9481642	01-Nov-2016
US	Granted	15/339378	31-Oct-2016	10028923	24-Jul-2018
US	Granted	15/339346	31-Oct-2016	10154972	18-Dec-2018
US	Granted	16/037963	17-Jul-2018	10668031	02-Jun-2020
US	Granted	16/223002	17-Dec-2018	11065215	20-Jul-2021
US	Published	17/375807	14-Jul-2021		
WO	Nationalized	PCT/US12/46335	11-Jul-2012		
CN	Published	201910957458.9	09-Oct-2019		
EA	Published	201491335	11-Jul-2012		
CN	Abandoned	201280070968.0	11-Jul-2012		
JP	Abandoned	2014-551231	11-Jul-2012		
JP	Abandoned	2017-079805	11-Jul-2012		
JP	Published	2019-165827	12-Sep-2019		

SCHEDULE

ZA	Granted	2014/05046	11-Jul-2012	2014/05046	25-Jan-2017
ZA	Granted	2016/06957	11-Jul-2012	2016/06957	30-May-2018
KR	Granted	10-2014-7021875	11-Jul-2012	10-2035879	17-Oct-2019
KR	Abandoned	10-2019-7030360	15-Oct-2019		
KR	Published	10-2020-7034195	26-Nov-2020		
JP	Published	2021-120385	21-Jul-2021		
AU	Granted	2012363873	11-Jul-2012	2012363873	
CL	Granted	01782-2014	11-Jul-2012	61278.	23-Oct-2020
CA	Granted	2862533	11-Jul-2012	2862533	04-May-2021
HK	Published	42020011068.2	14-Jul-2020		
HK	Granted	15104435.8	11-Jul-2012	HK1203829	23-Apr-2021
MX	Granted	MX/a/2014/008190	11-Jul-2012	372488	20-Mar-2020
BR	Granted	1120140168083	11-Jul-2012	BR112014016808-3	11-Jan-2022
MX	Pending	MX/a/2020/003112	19-Mar-2020		
IL	Granted	233506	11-Jul-2012	233506	31-Jul-2018

SCHEDULE

EP	Granted, Validated in BE, FR, DE, IT, IE, NL, ES, SE, CH, and GB	12738330.5	11- Jul- 2012	2800561	19- Aug- 2020
SG	Abandoned	11201403839S	11- Jul- 2012		
SG	Published	10201911743T	05- Dec- 2019		

US	Granted	14/414091	09-Jan- 2015	9572784	21-Feb- 2017
US	Granted	15/433987	15-Feb- 2017	10159658	25-Dec- 2018
WO	Nationalized	PCT/US13/50142	11-Jul- 2013		

US	Granted	13/734966	05-Jan- 2013	9211263	15-Dec- 2015
US	Granted	14/370450	02-Jul- 2014	10201511	12-Feb- 2019
US	Granted	14/968696	14- Dec- 2015	9770422	26-Sep- 2017
US	Granted	15/712026	21-Sep- 2017	10603291	31- Mar- 2020
US	Published	16/273079	11-Feb- 2019		
WO	Nationalized	PCT/US13/20420	05-Jan- 2013		
CN	Published	201910790329.5	26- Aug- 2019		
EA	Granted, Validated in RU	201491334	05-Jan- 2013	033067	30- Aug- 2019
CN	Abandoned	201380012680.2	05-Jan- 2013		
JP	Granted	2014-551381	05-Jan- 2013	6175074	14-Jul- 2017
JP	Granted	2017-133184	05-Jan- 2013	6581625	06-Sep- 2019

SCHEDULE

JP	Published	2019-157580	30-Aug-2019		
ZA	Granted	2014/04676	05-Jan-2013	2014/04676	30-May-2018
JP	Published	2021-166550	11-Oct-2021		
KR	Granted	10-2014-7021873	05-Jan-2013	10-2231554	18-Mar-2021
AU	Granted	2013207329	05-Jan-2013	2013207329	08-Feb-2018
NZ	Granted	626578	05-Jan-2013	626578	28-Feb-2017
CA	Granted	2860669	05-Jan-2013	2860669	03-May-2022
HK	Published	42020011126.8	14-Jul-2020		
HK	Published	15104436.7	11-May-2015		
MX	Granted	MX/a/2014/008189	05-Jan-2013	379226	21-Jan-2021
BR	Pending	1120140168105	05-Jan-2013		
MX	Pending	MX/a/2021/000715	14-Jan-2021		
US	Expired	61/649171	18-May-2012		
IL	Granted	233333	05-Jan-2013	233333	01-Feb-2022
EP	Published	13729824.6	05-Jan-2013		
SG	Granted	11201403873U	05-Jan-2013	11201403873	09-Apr-2019

US	Published	14/147449	03-Jan-2014		
US	Published	16/695498	26-Nov-2019		

SCHEDULE

MO	Granted	J/005889	18-Mar-2022	J/005889	11-May-2022
WO	Nationalized	PCT/US14/10240	03-Jan-2014		
CN	Granted	201910033955.X	03-Jan-2014	ZL201910033955.X	01-Feb-2022
EA	Granted, Validated in KZ, AZ, BY, AM, KG, TJ, TM, RU	201591085	03-Jan-2014	039530	08-Feb-2022
CN	Granted	201480003932.X	03-Jul-2015	105101956	07-Dec-2018
JP	Granted	2015-551792	03-Jan-2014	6333855	11-May-2018
ZA	Granted	2015/04858	03-Jan-2014	2015/04858	19-Dec-2018
KR	Granted	10-2015-7019855	03-Jan-2014	10-2229492	12-Mar-2021
AR	Published	2014100044	06-Jan-2014		
AU	Granted	2014203942	03-Jan-2014	2014203942	18-Apr-2019
CL	Pending	201501914	03-Jan-2014		
NZ	Granted	709525	03-Jan-2014	709525	03-Nov-2020
CA	Granted	2896864	03-Jan-2014	2896864	20-Apr-2021
HK	Published	42020001762.2	21-Jan-2020		

SCHEDULE

HK	Published	16103014.8	15-Mar-2016		
MX	Granted	MX/A/2015/008625	03-Jan-2014	376822	02-Nov-2020
BR	Published	1120150161111	03-Jan-2014		
MX	Granted	MX/a/2020/011594	30-Oct-2020	389344	13-Jan-2022
PH	Allowed	1-2015-501520	03-Jan-2014		
US	Expired	61/749307	05-Jan-2013		
IL	Granted	239722	03-Jan-2014	239722	02-Jul-2022
IN	Granted	5858/DELNP/2015	03-Jan-2014	335902	23-Apr-2020
EP	Published	14702108.3	05-Aug-2015		
SG	Abandoned	11201505240Q	03-Jan-2014		
SG	Pending	10201705437S	03-Jan-2014		